source
- Roche reports positive interim Phase 3 results for kidney drug, paving way for accelerated approvalRoche announced interim results from its Phase 3 trial of a kidney disease therapy, indicating the study met its primary endpoints. The data, released on Wednesday, suggest the drug could qualify…
- Roivant's FcRn drug IMVT-1402 fails Phase 2b lupus trialRoivant announced that its FcRn-targeting antibody IMVT-1402 (imeroprubart) failed to meet primary endpoints in a Phase 2b trial in patients with lupus. The study did not show improvement in disea…